诺和诺德明年大幅下调减肥神药在美售价，降幅最高50%

Core Viewpoint - Novo Nordisk has announced a significant price reduction for its weight loss drugs Wegovy and Ozempic in the U.S. market, with a new monthly price of $675, representing a reduction of up to 50%, effective January 1 next year. This marks a major shift in the company's competitive strategy in the obesity market [1][3]. Group 1 - The price cut is a proactive response from Novo Nordisk after losing its leading position in the obesity market, creating a clear price advantage over Eli Lilly's competing product Zepbound, which is priced at $1,086.37 per month [3]. - Novo Nordisk's U.S. business head, Jamey Millar, stated that the price reduction will not directly impact the company's net sales but is optimistic about gaining payer acceptance. Millar has experience in U.S. drug pricing strategies and believes payers will welcome the lower prices [3]. - The price reduction primarily targets wholesale acquisition costs and does not reflect the complex discount and rebate system in the U.S. market. Under commercial insurance, patients' out-of-pocket costs for Zepbound and Wegovy can currently be as low as $25 per month [3]. Group 2 - High-deductible health plan patients will benefit the most from this price reduction, as their out-of-pocket costs are more closely tied to drug prices. Patients under plans with coinsurance designs will also see benefits [3]. - According to the Kaiser Family Foundation (KFF) employer health benefits survey, last year about one-third of employees with employer insurance were enrolled in high-deductible health plans. However, less than half of large employers covered GLP-1 weight loss drugs like Wegovy [4]. - The price reduction will coincide with discounts obtained from negotiations with the U.S. government regarding Medicare, although Millar emphasized that these two price reduction measures are independent and not related [4].